Mostly Markets
Subscribe
Stocks/Health Care/Pharmaceuticals

Novo NordiskNVO

Pharmaceuticals
Cheaper than peers
$40.00+2.20%After hours: $39.97 (−0.08%)At the close, 30 Oct · Prices from CNBC, may be delayed
▼ 22.1% over 1 year
Novo Nordisk over 1 yearDaily close, $, to 30 Oct 2026
$50$60Nov2026MarMayJulSep$40.00$60NovMarJul$40.00
Source: Nasdaq daily closes
Market value$136B
Price to earnings10.0x
Forward P/E12.2x
Dividend yield4.49%
Year to date−21.4%
One year−22.1%
Next earningsWed 4 Nov, before the open
SectorHealth Care
52-week range (closes)
$35.29$63.98

Quality and valuation

How Novo Nordisk compares with other health care stocks. A description, not a recommendation.

Novo Nordisk and 4 pharmaceuticals peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Valuation: cheaper than most

Next to other health care companies, it is, priced below most of them.

Novo Nordisk trades at 12.2 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover.

    NVO trades at 12.2x forward earnings, below the sector medianForward p/e, Pharmaceuticals peers
    BMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1xBMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1x
    Source: CNBC quotes; Mostly Markets

    Stories on Novo Nordisk

    We haven't written about Novo Nordisk yet. Follow it, and its first story will show under My stocks on the front page.

    Similar companies

    Pharmaceuticals, by market value.

    CompanyPriceTodayYTDValue
    LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
    JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
    MRKMerck$149.52+2.18%+42.0%$369B
    NVSNovartis$160.79−0.19%+16.6%$327B
    AZNAstraZeneca$186.65+7.02%+6.4%$290B
    PFEPfizer$30.52+1.90%+22.6%$174B
    BMYBristol Myers Squibb$62.48+1.78%+15.8%$128B
    ZTSZoetis$79.72+1.85%−37.4%$32.94B